Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?
Adjuvant (ADJ) systemic therapy has transformed melanoma treatment during the past decade. There are, however, still important unanswered questions that lead to debates on the utility and place of ADJ therapy for melanoma. When ADJ trials are reported, they present a hazard ratio with a significant...
Saved in:
| Main Authors: | Alexander C.J. van Akkooi, Mario Mandala, Paul Nathan, Andrew Haydon, Michael Postow, Piotr Rutkowski |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-12-01
|
| Series: | EJC Skin Cancer |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2772611824000053 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Xanomeline and Trospium Chloride Versus Placebo for the Treatment of Schizophrenia: A Post Hoc Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to Be Helped or Harmed
by: Citrome L, et al.
Published: (2025-04-01) -
Early-Stage Renal Cell Carcinoma: Who Needs Adjuvant Therapy?
by: Andreea Ioana Parosanu, et al.
Published: (2025-02-01) -
Freund’s adjuvant is a classic of vaccine adjuvants and the basis of experimental immunology
by: F.V. Hladkykh
Published: (2024-11-01) -
An update on adjuvant systemic therapies in melanoma
by: Evangeline Samuel, et al.
Published: (2019-11-01) -
[Comment] Clinical outcomes of ileostomy closure during versus after adjuvant chemotherapy in patients with rectal cancer
by: Zhao Zeyun, et al.
Published: (2024-06-01)